Knapper, Steven - Cardiff University

个人简介

I am an academic clinical haematologist, combining the role of Clinical Reader in the Institute of Cancer and Genetics at Cardiff University School of Medicine with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales where I currently act as haematological cancer lead clinician. My clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia, the myeloproliferative neoplasms and myelodysplastic syndromes. My chief research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes pre-clinical laboratory studies on FLT3 inhibition, TAM kinase inhibition and reactive oxygen species manipulation and clinical research including 'back to bench' laboratory projects running alongside clinical trials. I am extensively involved in the development of clinical research at a national level through membership of the UK NCRI AML and Myeloproliferative Neoplasms Clinical Study Groups. I co-lead on early phase clinical trials within the Welsh Cancer Research Centre. I am chief investigator of MONOCLE - a UK study of tefinostat in chronic myelomonocytic leukaemia, and co-chief investigator of the AML18 trial. My other roles include Cardiff lead for the Bloodwise Trials Acceleration Programme and lead of Cardiff University School of Medicine medical undergraduate haematology teaching.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Williams, J.et al. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology pdf Beauverd, Y.et al. 2016. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101(5), pp. e182-e184. (10.3324/haematol.2015.139691) pdf Zabkiewicz, J.et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7(13), pp. 16650-16662. (10.18632/oncotarget.7692) pdf Burnett, A.et al. 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 16(13), pp. 1295-1305. (10.1016/S1470-2045(15)00193-X) Knapper, S. 2015. The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia. Haematologica 100(9), pp. 1105-1107. (10.3324/haematol.2015.134023) Coles, S.et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29(9), pp. 1952. (10.1038/leu.2015.62) Andersen, C.et al. 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 38(7), pp. 816-821. (10.1016/j.leukres.2014.04.002) Knapper, S.et al. 2014. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research 38(3), pp. 346-351. (10.1016/j.leukres.2013.12.011) Burnett, A.et al. 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122(8), pp. 1384-1394. (10.1182/blood-2013-04-496596) Moore, A.et al. 2013. Novel therapies for children with acute myeloid leukaemia. Leukemia 27(7), pp. 1451-1460. (10.1038/leu.2013.106)